Cost-effectiveness of screening for prostate cancer
https://doi.org/10.17650/1726-9776-2007-3-4-36-40
Abstract
The total expenses on the early detection and further treatment of prostate cancer (PC) were analyzed in 1785 males aged 40 to 70 years, examined at the Russian Radiology Research Center, for prostate pathology-unassociated diseases in 2000—2005. A control group comprised 734 patients referred to urologist of the Russian Radiology Research Center Polyclinic during the same period. In the study group, the cost of treatment per patient with detected PC was 60,150 rbl (including that of screening) while in the control group, it was 150,376 rbl. The expected economic effect of introduction of a PC screening program at the federal level may be as many as 8,970,066,799.48 rbl.
About the Authors
A. D. Kaprin
Russian Medical Academy of Postgraduate Education; Russian Radiology Research Center, Russian Agency for Health Care
Russian Federation
Russian Federation
Department of Health Care and Public Health Organization
Moscow
N. B. Naigovzina
Russian Medical Academy of Postgraduate Education; Russian Radiology Research Center, Russian Agency for Health Care
Russian Federation
Russian Federation
Department of Health Care and Public Health Organization
Moscow
S. A. Ivanov
Russian Medical Academy of Postgraduate Education; Russian Radiology Research Center, Russian Agency for Health Care
Russian Federation
Russian Federation
Department of Health Care and Public Health Organization
Moscow
V. A. Bashmakov
Russian Medical Academy of Postgraduate Education; Russian Radiology Research Center, Russian Agency for Health Care
Russian Federation
Russian Federation
Department of Health Care and Public Health Organization
Moscow
References
1. Харченко В.П., Гафанов Р.А., Каприн А.Д. Гормонорезистентный рак предстательной железы. Возможности лечения: Обзор. Андрол и генитал хир 2001;(4):8—12.
2. Корчагин В.П., Найговзина Н.Б. Организационно-экономические аспекты реализации концепции развития здравоохранения и медицинской науки в Российской Федерации. Экон здравоохр 1998;(8):12—6.
3. Postma R., Roobol M., Schroder F.H., van der Kwast T.H. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 2004;100:968—75.
4. Holmberg H., Carlsson P., Lofman O., Varenhorst E. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden. Health Policy 1998;45(2):133—47.
5. Makinen T., Tammela T.L., Stenman U.H. et al. Second round results of the Finish population-based prostate cancer screening trial. Clin Cancer Res 2004;(10):2231—6.
6. Hugosson O., Aus G., Lilja H. et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397—405.
7. Roberts R.O. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999;161(2):529—33.
8. Albertsen P.C., Hanley J.A., Harlan L.C. et al. The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: A population based analysis. J Urol 2000;163:1138.
Review
For citations:
Kaprin A.D., Naigovzina N.B., Ivanov S.A., Bashmakov V.A. Cost-effectiveness of screening for prostate cancer. Cancer Urology. 2007;3(4):36-40. (In Russ.) https://doi.org/10.17650/1726-9776-2007-3-4-36-40
Views:
289
Email this article 